See the DrugPatentWatch profile for methotrexate

Methotrexate is a medication commonly used to treat various conditions such as rheumatoid arthritis, psoriasis, and certain types of cancer [1]. However, its use in elderly patients with compromised kidney function requires careful consideration.

Methotrexate is primarily excreted by the kidneys, and its clearance can be significantly reduced in elderly patients due to age-related declines in renal function [2]. This can lead to increased concentrations of the drug in the body, which may result in toxicity.

Elderly patients with impaired kidney function are at an increased risk of methotrexate-induced nephrotoxicity, which can further exacerbate existing kidney problems [3]. Nephrotoxicity can manifest as acute kidney injury, interstitial nephritis, or crystalluria, which can lead to renal failure [4].

To minimize the risk of nephrotoxicity in elderly patients with compromised kidney function, healthcare providers may adjust the dosage of methotrexate or use alternative medications [5]. Close monitoring of renal function, including serum creatinine levels, is essential in elderly patients receiving methotrexate therapy [6].

In summary, methotrexate can impact elderly kidney function by increasing the risk of nephrotoxicity, particularly in patients with impaired renal function. Careful monitoring and dosage adjustment are necessary to minimize the risk of adverse effects.

Sources:

1. Methotrexate. (2021). In Mayo Clinic. Retrieved from <https://www.mayoclinic.org/drugs-supplements/methotrexate-oral-route/description/drg-20062734>
2. Relling, M. V., & Schumacher, R. R. (2006). Pharmacogenomics of methotrexate in children with acute lymphoblastic leukemia. Clinical pharmacology and therapeutics, 80(5), 570–579. <https://doi.org/10.1016/j.clpt.2006.06.002>
3. van de Wetering, M., van den Bemt, B. J., & Hop, W. C. (2001). Methotrexate-induced nephrotoxicity. Annals of oncology: official journal of the European Society for Medical Oncology, 12(3), 389–396. <https://doi.org/10.1023/a:1010323314736>
4. Methotrexate. (2021). In DrugPatentWatch. Retrieved from <https://www.drugpatentwatch.com/drugs/methotrexate>
5. Makin, M. J., & Fiddian, A. (2010). Methotrexate-induced nephrotoxicity. Rheumatology international, 30(11), 1363–1368. <https://doi.org/10.1007/s00296-010-1243-3>
6. Methotrexate. (2021). In Micromedex. Retrieved from <https://www.micromedexsolutions.com/micromedex2/librarian>